Flamel maintained by Merrill Lynch at sell

Flamel Technologies SA was maintained by Merrill Lynch analyst Hari Sambasivam at a sell rating following interim phase I/II data for its IFN-alpha-XL in chronic hepatitis C virus infection. In the United States, Flamel shares Friday were down $0.64, or 3.67%, at $16.79 on volume of 319.022 shares versus the three-month running average of 242,725 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.